Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,otherCurrentAssets,retainedEarnings,otherLiab,goodWill,treasuryStock,otherAssets,cash,totalCurrentLiabilities,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,longTermInvestments,shortTermInvestments,netReceivables,longTermDebt,investments,changeToLiabilities,totalCashflowsFromInvestingActivities,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,effectOfExchangeRate,totalCashFromOperatingActivities,depreciation,otherCashflowsFromInvestingActivities,changeToAccountReceivables,otherCashflowsFromFinancingActivities,changeToNetincome,capitalExpenditures,netBorrowings,WC,language,region,quoteType,triggerable,quoteSourceName,market,currency,twoHundredDayAverageChangePercent,exchangeDataDelayedBy,marketState,exchange,esgPopulated,tradeable,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,priceHint,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,gmtOffSetMilliseconds,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,marketCap,shortName,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (Jul 14, 2021) 4","Short Ratio (Jul 14, 2021) 4","Short % of Float (Jul 14, 2021) 4","Short % of Shares Outstanding (Jul 14, 2021) 4","Shares Short (prior month Jun 14, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,longBusinessSummary,city,phone,country,website,maxAge,address1,industry,address2
t0,IMAB,5344127000.0,75241904,286228000,,1053781000,,1041550000,91634000,1542668000,1164806000,1164806000,,,,,,12231000,1542668000,377862000,0,-111025000,,1041550000,1041550000,120444000.0,7701116000.0,706648000.0,5627145000.0,138719000.0,6333793000.0,114000.0,84906000.0,-2023292000.0,124981000.0,162574000.0,-50793000.0,2010000.0,4758778000.0,576125000.0,-50793000.0,40269000.0,5343664000.0,664832000.0,31530000.0,465900000.0,,5727000.0,-129000.0,54480000.0,844789000.0,126474000.0,845296000.0,1798761000.0,-116697000.0,1016189000.0,6228000.0,52000000.0,-357889000.0,-507000.0,198399000.0,-3247000.0,,4767539000.0,en-US,US,EQUITY,True,Delayed Quote,us_market,USD,0.10083717,0,PRE,NGM,False,False,71.81,1630526403,0.8899994,69.99,72.97,68.96,493929,15,America/New_York,EDT,2,1.2549343,68.96 - 72.97,70.92,0.0,0.0,8,8,finmb_642067965,NasdaqGM,I-Mab,CNY,600831,587528,39.171997,1.200196,32.638 - 85.4,-13.590004,-0.15913354,32.638,85.4,1617004800,1617004800,1617004800,-14400000,71.321144,0.48885345,0.006854257,65.23217,6.5778275,5403121152,I-MAB,,,,85.4,32.64,71.32,65.23,600.83k,587.53k,75.24M,,30.44M,0.84%,38.62%,1.78M,3.89,,2.31%,2.16M,,,,,,0.00%,,,,,"Dec 30, 2020","Dec 30, 2020",30.53%,10.08%,2.41%,14.06%,1.54B,26.45,,1.54B,168.31M,470.92M,,,4.79B,66.16,13.6M,0.24,9.27,,433.56M,279.43M,Value,201210,Healthcare,228,"I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase III clinical trials to treat multiple myeloma and autoimmune diseases; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 1a clinical trials with RBC-sparing differentiation; and Olamkicept, an IL-6 blocker that has completed Phase 2 clinical trials for the treatment of ulcerative colitis and autoimmune. Its product candidates also includes Enoblituzumab, a humanized B7-H3 antibody that is in Phase 2 to treat head and neck cancer, and other oncology diseases; Efineptakin, a long-acting recombinant human IL-7, which is in Phase 2 clinical trials to treat glioblastoma multiforme patients with lymphopenia; TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Plonmarlimab, a GM-CSF monoclonal antibody that is in Phase 2 clinical trials for rheumatoid arthritis and CAR-T-related therapies; Uliledlimab, a CD73 antibody, which is in Phase I/2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; and TJ-CD4B, a tumor-dependent T cell engager for gastric and other cancers. Its product candidates in pre-clinical development stage comprises TJX7, a novel CXCL13 antibody for autoimmune diseases; and TJ-C4GM antibodies for treating oncology diseases. I-Mab has strategic collaboration agreement with AbbVie Ireland Unlimited Company; and PT Kalbe Genexine Biologics. The company was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.",Shanghai,86 21 6057 8000,China,http://www.i-mabbiopharma.com,86400,"West Tower, OmniVision",Biotechnology,Suite 802 88 Shangke Road Pudong District
t-1,IMAB,3457061000.0,75241904,256170000,,12218000,,12218000,139391000,0,-395561000,-395561000,,-297000.0,,,,0,0,395561000,0,407779000,,12218000,12218000,122000000.0,6720714000.0,556437000.0,3741635000.0,103053000.0,4298072000.0,106000.0,107330000.0,-3064842000.0,137093000.0,162574000.0,85657000.0,,2960017000.0,349396000.0,85657000.0,42119000.0,3208382000.0,762997000.0,28526000.0,110787000.0,64771000.0,-24458000.0,-122000.0,-286735000.0,1941894000.0,-3493000.0,2003841000.0,1399986000.0,-22335000.0,-232838000.0,5518000.0,52000000.0,-357889000.0,-61947000.0,-246959000.0,-4626000.0,,2858986000.0,en-US,US,EQUITY,True,Delayed Quote,us_market,USD,0.10083717,0,PRE,NGM,False,False,71.81,1630526403,0.8899994,69.99,72.97,68.96,493929,15,America/New_York,EDT,2,1.2549343,68.96 - 72.97,70.92,0.0,0.0,8,8,finmb_642067965,NasdaqGM,I-Mab,CNY,600831,587528,39.171997,1.200196,32.638 - 85.4,-13.590004,-0.15913354,32.638,85.4,1617004800,1617004800,1617004800,-14400000,71.321144,0.48885345,0.006854257,65.23217,6.5778275,5403121152,I-MAB,,,,85.4,32.64,71.32,65.23,600.83k,587.53k,75.24M,,30.44M,0.84%,38.62%,1.78M,3.89,,2.31%,2.16M,,,,,,0.00%,,,,,"Dec 30, 2020","Dec 30, 2020",30.53%,10.08%,2.41%,14.06%,1.54B,26.45,,1.54B,168.31M,470.92M,,,4.79B,66.16,13.6M,0.24,9.27,,433.56M,279.43M,Value,201210,Healthcare,228,"I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase III clinical trials to treat multiple myeloma and autoimmune diseases; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 1a clinical trials with RBC-sparing differentiation; and Olamkicept, an IL-6 blocker that has completed Phase 2 clinical trials for the treatment of ulcerative colitis and autoimmune. Its product candidates also includes Enoblituzumab, a humanized B7-H3 antibody that is in Phase 2 to treat head and neck cancer, and other oncology diseases; Efineptakin, a long-acting recombinant human IL-7, which is in Phase 2 clinical trials to treat glioblastoma multiforme patients with lymphopenia; TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Plonmarlimab, a GM-CSF monoclonal antibody that is in Phase 2 clinical trials for rheumatoid arthritis and CAR-T-related therapies; Uliledlimab, a CD73 antibody, which is in Phase I/2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; and TJ-CD4B, a tumor-dependent T cell engager for gastric and other cancers. Its product candidates in pre-clinical development stage comprises TJX7, a novel CXCL13 antibody for autoimmune diseases; and TJ-C4GM antibodies for treating oncology diseases. I-Mab has strategic collaboration agreement with AbbVie Ireland Unlimited Company; and PT Kalbe Genexine Biologics. The company was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.",Shanghai,86 21 6057 8000,China,http://www.i-mabbiopharma.com,86400,"West Tower, OmniVision",Biotechnology,Suite 802 88 Shangke Road Pudong District
t-2,IMAB,1392458000.0,75241904,221145500,,-291426500,,-291426500,85692000,0,-306837500,-306837500,,-478500.0,,,,0,0,306837500,0,15411000,,-291426500,-291426500,148844000.0,4675991000.0,344846000.0,1703876000.0,7724000.0,2048722000.0,92000.0,84220000.0,-3077060000.0,17184000.0,162574000.0,104853000.0,,1560031000.0,251270000.0,104853000.0,44217000.0,1693087000.0,,1926000.0,45757000.0,69138000.0,15244500.0,1920000.0,15177000.0,326899000.0,-4661500.0,351899000.0,183374000.0,16194500.0,-174896500.0,4577500.0,52000000.0,-357889000.0,-61947000.0,114694000.0,-67500.0,-25000000.0,1441817000.0,en-US,US,EQUITY,True,Delayed Quote,us_market,USD,0.10083717,0,PRE,NGM,False,False,71.81,1630526403,0.8899994,69.99,72.97,68.96,493929,15,America/New_York,EDT,2,1.2549343,68.96 - 72.97,70.92,0.0,0.0,8,8,finmb_642067965,NasdaqGM,I-Mab,CNY,600831,587528,39.171997,1.200196,32.638 - 85.4,-13.590004,-0.15913354,32.638,85.4,1617004800,1617004800,1617004800,-14400000,71.321144,0.48885345,0.006854257,65.23217,6.5778275,5403121152,I-MAB,,,,85.4,32.64,71.32,65.23,600.83k,587.53k,75.24M,,30.44M,0.84%,38.62%,1.78M,3.89,,2.31%,2.16M,,,,,,0.00%,,,,,"Dec 30, 2020","Dec 30, 2020",30.53%,10.08%,2.41%,14.06%,1.54B,26.45,,1.54B,168.31M,470.92M,,,4.79B,66.16,13.6M,0.24,9.27,,433.56M,279.43M,Value,201210,Healthcare,228,"I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase III clinical trials to treat multiple myeloma and autoimmune diseases; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 1a clinical trials with RBC-sparing differentiation; and Olamkicept, an IL-6 blocker that has completed Phase 2 clinical trials for the treatment of ulcerative colitis and autoimmune. Its product candidates also includes Enoblituzumab, a humanized B7-H3 antibody that is in Phase 2 to treat head and neck cancer, and other oncology diseases; Efineptakin, a long-acting recombinant human IL-7, which is in Phase 2 clinical trials to treat glioblastoma multiforme patients with lymphopenia; TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Plonmarlimab, a GM-CSF monoclonal antibody that is in Phase 2 clinical trials for rheumatoid arthritis and CAR-T-related therapies; Uliledlimab, a CD73 antibody, which is in Phase I/2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; and TJ-CD4B, a tumor-dependent T cell engager for gastric and other cancers. Its product candidates in pre-clinical development stage comprises TJX7, a novel CXCL13 antibody for autoimmune diseases; and TJ-C4GM antibodies for treating oncology diseases. I-Mab has strategic collaboration agreement with AbbVie Ireland Unlimited Company; and PT Kalbe Genexine Biologics. The company was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.",Shanghai,86 21 6057 8000,China,http://www.i-mabbiopharma.com,86400,"West Tower, OmniVision",Biotechnology,Suite 802 88 Shangke Road Pudong District
t-3,IMAB,1392458000.0,75241904,221145500,,-291426500,,-291426500,85692000,0,-306837500,-306837500,,-478500.0,,,,0,0,306837500,0,15411000,,-291426500,-291426500,148844000.0,4675991000.0,344846000.0,1703876000.0,7724000.0,2048722000.0,92000.0,84220000.0,-3077060000.0,17184000.0,162574000.0,104853000.0,,1560031000.0,251270000.0,104853000.0,44217000.0,1693087000.0,,1926000.0,45757000.0,69138000.0,15244500.0,1920000.0,15177000.0,326899000.0,-4661500.0,351899000.0,183374000.0,16194500.0,-174896500.0,4577500.0,52000000.0,-357889000.0,-61947000.0,114694000.0,-67500.0,-25000000.0,1441817000.0,en-US,US,EQUITY,True,Delayed Quote,us_market,USD,0.10083717,0,PRE,NGM,False,False,71.81,1630526403,0.8899994,69.99,72.97,68.96,493929,15,America/New_York,EDT,2,1.2549343,68.96 - 72.97,70.92,0.0,0.0,8,8,finmb_642067965,NasdaqGM,I-Mab,CNY,600831,587528,39.171997,1.200196,32.638 - 85.4,-13.590004,-0.15913354,32.638,85.4,1617004800,1617004800,1617004800,-14400000,71.321144,0.48885345,0.006854257,65.23217,6.5778275,5403121152,I-MAB,,,,85.4,32.64,71.32,65.23,600.83k,587.53k,75.24M,,30.44M,0.84%,38.62%,1.78M,3.89,,2.31%,2.16M,,,,,,0.00%,,,,,"Dec 30, 2020","Dec 30, 2020",30.53%,10.08%,2.41%,14.06%,1.54B,26.45,,1.54B,168.31M,470.92M,,,4.79B,66.16,13.6M,0.24,9.27,,433.56M,279.43M,Value,201210,Healthcare,228,"I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase III clinical trials to treat multiple myeloma and autoimmune diseases; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 1a clinical trials with RBC-sparing differentiation; and Olamkicept, an IL-6 blocker that has completed Phase 2 clinical trials for the treatment of ulcerative colitis and autoimmune. Its product candidates also includes Enoblituzumab, a humanized B7-H3 antibody that is in Phase 2 to treat head and neck cancer, and other oncology diseases; Efineptakin, a long-acting recombinant human IL-7, which is in Phase 2 clinical trials to treat glioblastoma multiforme patients with lymphopenia; TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Plonmarlimab, a GM-CSF monoclonal antibody that is in Phase 2 clinical trials for rheumatoid arthritis and CAR-T-related therapies; Uliledlimab, a CD73 antibody, which is in Phase I/2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; and TJ-CD4B, a tumor-dependent T cell engager for gastric and other cancers. Its product candidates in pre-clinical development stage comprises TJX7, a novel CXCL13 antibody for autoimmune diseases; and TJ-C4GM antibodies for treating oncology diseases. I-Mab has strategic collaboration agreement with AbbVie Ireland Unlimited Company; and PT Kalbe Genexine Biologics. The company was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.",Shanghai,86 21 6057 8000,China,http://www.i-mabbiopharma.com,86400,"West Tower, OmniVision",Biotechnology,Suite 802 88 Shangke Road Pudong District
